公司资料
Sana Biotechnology 股价、新闻与催化剂
- 股票代码:
- SANA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
3.74 USD (-8.78%)
收盘价
最后更新: 2026年8月20日
902M USD
市值
股价为何变动
As of Aug 20, 2026, SANA closed down 8.78% at $3.74. No new same-company headline was identified in the current news window.
公司概览
Engineered Cell Therapies
Sana Biotechnology develops engineered cells intended to repair or replace damaged biology while overcoming immune rejection. Its platform spans ex vivo cell replacement and in vivo delivery technologies.
SC451 Islet-Cell Therapy
SC451 is a gene-modified, stem-cell-derived pancreatic islet-cell candidate designed to restore insulin production in people with type 1 diabetes without chronic immunosuppression. Sana is advancing the program in collaboration with Mayo Clinic.
UP421 Clinical Validation
UP421 is a hypoimmune-modified primary islet-cell therapy being evaluated in an investigator-sponsored study without immunosuppression. Survival and insulin-producing function observed after transplantation provide human validation for the immune-evasion technology used in SC451.
SG293 In Vivo CAR-T
SG293 uses a CD8-targeted fusosome to deliver genetic material that creates CD19-directed CAR-T cells inside the body. Sana plans to begin in non-Hodgkin lymphoma before potentially expanding into B-cell-mediated autoimmune diseases.
SG227 Multiple-Myeloma Program
SG227 applies the same in vivo delivery approach to a BCMA-directed CAR for multiple myeloma. Its clinical entry is contingent on the initial safety and efficacy profile of SG293.
未来催化剂
- IND submission and Phase 1/2 initiation for SC451 as early as 2026.
- First-in-human data for SG293 in non-Hodgkin lymphoma as early as 2026.
- Additional UP421 investigator-sponsored-study data at the EASD Annual Meeting on October 2, 2026.
- Clinical-study initiation for SG227 as early as mid-2027, contingent on the early SG293 clinical profile.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。